These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 26282650)

  • 1. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
    Salles GA; Morschhauser F; Solal-Céligny P; Thieblemont C; Lamy T; Tilly H; Gyan E; Lei G; Wenger M; Wassner-Fritsch E; Cartron G
    J Clin Oncol; 2013 Aug; 31(23):2920-6. PubMed ID: 23835715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
    Morschhauser FA; Cartron G; Thieblemont C; Solal-Céligny P; Haioun C; Bouabdallah R; Feugier P; Bouabdallah K; Asikanius E; Lei G; Wenger M; Wassner-Fritsch E; Salles GA
    J Clin Oncol; 2013 Aug; 31(23):2912-9. PubMed ID: 23835718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
    Cartron G; Hourcade-Potelleret F; Morschhauser F; Salles G; Wenger M; Truppel-Hartmann A; Carlile DJ
    Haematologica; 2016 Feb; 101(2):226-34. PubMed ID: 26659915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
    N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Ogura M; Tobinai K; Hatake K; Uchida T; Suzuki T; Kobayashi Y; Mori M; Terui Y; Yokoyama M; Hotta T
    Cancer Sci; 2013 Jan; 104(1):105-10. PubMed ID: 23046388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
    Salles G; Morschhauser F; Lamy T; Milpied N; Thieblemont C; Tilly H; Bieska G; Asikanius E; Carlile D; Birkett J; Pisa P; Cartron G
    Blood; 2012 May; 119(22):5126-32. PubMed ID: 22431570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab for the treatment of indolent lymphoma.
    Edelmann J; Gribben JG
    Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 15. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
    Sehn LH; Assouline SE; Stewart DA; Mangel J; Gascoyne RD; Fine G; Frances-Lasserre S; Carlile DJ; Crump M
    Blood; 2012 May; 119(22):5118-25. PubMed ID: 22438256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.